Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm 233 > Type 2 diabetes drugs > Flashcards

Type 2 diabetes drugs Flashcards

1
Q

canagliflozin (invokana)

A

SGLT2 inhibitor
-Prevent glucose reabsorption in kidney
-Blocks SGLT1
——–
-T2D
-does not cause hypoglycemia
-can be used as combo
—–
-gential and UTI
-may increase keto acidosis
-increased risk of amputation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Dapagliflozin (Forxiga)

A

SGLT2 inhibitor
-Prevent glucose reabsorption in kidney
——–
-T2D
-does not cause hypoglycemia
-can be used as combo
—–
-gential and UTI
-may increase keto acidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Empagliflozin

A

SGLT2 inhibitor
-Prevent glucose reabsorption in kidney
——–
-T2D
-does not cause hypoglycemia
-can be used as combo
—–
-gential and UTI
-may increase keto acidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ertugliflozin (steglatro)

A

SGLT2 inhibitor
-Prevent glucose reabsorption in kidney
——–
-T2D
-does not cause hypoglycemia
-can be used as combo
—–
-gential and UTI
-may increase keto acidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bexagliflozin (brenzavvy)

A

SGLT2 inhibitor
-Prevent glucose reabsorption in kidney
——–
-T2D
-does not cause hypoglycemia
-can be used as combo
—–
-gential and UTI
-may increase keto acidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

exenatide

A

GLP-1 agonist
-increase insulin
-decrease glucagon
-slow stomach emptying
-reduce appetite
——-
-T2D
-low risk of hypoglycemia
——–
-increased heart rate
-pancreatitis
-can have neutralizing antibodies develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Liraglutide

A

GLP-1 agonist
-increase insulin
-decrease glucagon
-slow stomach emptying
-reduce appetite
——-
-T2D
-low risk of hypoglycemia
——–
-increased heart rate
-pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Albiglutide

A

GLP-1 agonist
-increase insulin
-decrease glucagon
-slow stomach emptying
-reduce appetite
——-
-T2D
-low risk of hypoglycemia
——–
-increased heart rate
-pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lixisenatide

A

GLP-1 agonist
-increase insulin
-decrease glucagon
-slow stomach emptying
-reduce appetite
——-
-T2D
-low risk of hypoglycemia
——–
-increased heart rate
-pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

dulaglutide

A

GLP-1 agonist
-increase insulin
-decrease glucagon
-slow stomach emptying
-reduce appetite
——-
-T2D
-low risk of hypoglycemia
——–
-increased heart rate
-pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Semaglutide

A

GLP-1 agonist
-increase insulin
-decrease glucagon
-slow stomach emptying
-reduce appetite
——-
-T2D
-low risk of hypoglycemia
——–
-increased heart rate
-pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sitagliptin

A

DPP-4 inhibitor
-reduce the breakdown of GLP-1 peptide
——–
-T2D
-Oral medication is nicer
——–
-pancreatitis
-block degradation of other peptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

vildagliptin

A

DPP-4 inhibitor
-reduce the breakdown of GLP-1 peptide
——–
-T2D
-Oral medication is nicer
——–
-pancreatitis
-block degradation of other peptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

saxagliptin

A

DPP-4 inhibitor
-reduce the breakdown of GLP-1 peptide
——–
-T2D
-Oral medication is nicer
——–
-pancreatitis
-block degradation of other peptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

alogliptin

A

DPP-4 inhibitor
-reduce the breakdown of GLP-1 peptide
——–
-T2D
-Oral medication is nicer
——–
-pancreatitis
-block degradation of other peptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

linagliptin

A

DPP-4 inhibitor
-reduce the breakdown of GLP-1 peptide
——–
-T2D
-Oral medication is nicer
——–
-pancreatitis
-block degradation of other peptides

17
Q

Acarbose

A

alpha-glucosidase inhibitors
-prevent break down to absorbable mono saccharides
———
-T2D
———
-fltulence

18
Q

miglitol

A

alpha-glucosidase inhibitors
-prevent break down to absorbable mono saccharides
———
-T2D
———
-fltulence

19
Q

Voglibose

A

alpha-glucosidase inhibitors
-prevent break down to absorbable mono saccharides
———
-T2D
———
-fltulence

20
Q

Rosiglitazone

A

Insulin sensitizer
-Bind PPAR gamma, to induce glucose uptake into adipose tissues
———
-T2D
-takes 6-12 weeks to work
——–
-weight gain

21
Q

Pioglitazone

A

Insulin sensitizer
-Bind PPAR gamma, to induce glucose uptake into adipose tissues
———
-T2D
-takes 6-12 weeks to work
——–
-weight gain

22
Q

Troglitazone

A

Insulin sensitizer
-Bind PPAR gamma, to induce glucose uptake into adipose tissues
———
-T2D
-takes 6-12 weeks to work
——–
-weight gain

23
Q

Tolbutamide

A

1st gen secretagogues
-Bind K+ channels causing depol and insulin release
——–
-T2D
———
-cardiac issues from K+ binding
-hypoglycemia
-weight gain

24
Q

Chlorpropamide

A

1st gen secretagogues
-Bind K+ channels causing depol and insulin release
——–
-T2D
———
-cardiac issues from K+ binding
-hypoglycemia
-weight gain

25
Q

Acetohexamide

A

1st gen secretagogues
-Bind K+ channels causing depol and insulin release
——–
-T2D
———
-cardiac issues from K+ binding
-hypoglycemia
-weight gain

26
Q

Glyburide

A

2nd gen secretagogues
-Bind different K+ channels causing depol and insulin release
——–
-T2D
———
-cardiac issues from K+ binding Less than 1st gen
-hypoglycemia
-weight gain

27
Q

Glipizide

A

2nd gen secretagogues
-Bind different K+ channels causing depol and insulin release
——–
-T2D
———
-cardiac issues from K+ binding Less than 1st gen
-hypoglycemia
-weight gain

28
Q

Glimepiride

A

2nd gen secretagogues (maybe 3rd)
-Bind K+ channels causing depol and insulin release
——–
-T2D
———
-cardiac issues from K+ binding Less than 1st gen
-hypoglycemia
-weight gain

29
Q

Repaglinide

A

Non-sulfonylurea secretagogue
-bind different location on K+ channels causing insulin release
-rapid on/off
——–
-T2D
——–
-Less hypoglycemia
-weight gain

30
Q

Nateglinide

A

Non-sulfonylurea secretagogue
-bind different location on K+ channels causing insulin release
-rapid on/off
——–
-T2D
——–
-Less hypoglycemia
-weight gain

Pharm 233 (57 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions